Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis
NCT01533714 · UCB BIOSCIENCES, Inc. · PHASE2 · terminated · last registry update 2022-05-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Decision to out-license the compound for further development” | – | Registry record, UCB BIOSCIENCES, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-03-14Results posted on the registry: University Hospital, Ghent, Anakinra + Siltuximab (NCT04330638)
- 2022-12-05Phase 3 first posted: Novo Nordisk A/S, Ziltivekimab + Placebo (NCT05636176)
- 2022-08-03Phase 3 first posted: CSL Behring, CSL300 + Placebo (NCT05485961)
- 2022-06-21Results posted on the registry: Janssen Pharmaceutica N.V., Belgium, Sirukumab + Placebo (NCT04380961)
- 2022-06-07Results posted on the registry: R-Pharm International, LLC, Olokizumab 64 mg SC q4w + Olokizumab 64 mg SC q2w (NCT03120949)
- 2022-04-14Results posted on the registry: UCB BIOSCIENCES, Inc., CDP6038 (olokizumab) (NCT01296711)
- 2022-04-14Also stopped (terminated): UCB BIOSCIENCES, Inc., CDP6038 (olokizumab) (NCT01296711)
- 2022-04-08Results posted on the registry: Columbia University, Clazakizumab (NCT04381052)
- 2022-04-08Also stopped (terminated): Columbia University, Clazakizumab (NCT04381052)
- 2022-02-15Results posted on the registry: NYU Langone Health, Clazakizumab 25 mg + Clazakizumab 12.5 mg (NCT04343989)
- 2022-01-24Results posted on the registry: R-Pharm International, LLC, RPH-104 80 mg + Olokizumab 64 mg (NCT04380519)
- 2022-01-12Phase 3 first posted: R-Pharm, Olokizumab + Standard therapy (NCT05187793)
- 2021-12-06Results posted on the registry: CSL Behring, BMS-945429 Placebo + BMS-945429 (NCT01373151)
- 2021-12-03Results posted on the registry: CSL Behring, Placebo matching with BMS-945429 + Placebo matching with BMS-945429 (NCT01545050)
- 2021-12-03Also stopped (terminated): CSL Behring, Placebo matching with BMS-945429 + Placebo matching with BMS-945429 (NCT01545050)
- 2021-12-02Results posted on the registry: Cedars-Sinai Medical Center, Clazakizumab (NCT04348500)
- 2021-11-08Also stopped (withdrawn): R-Pharm, Olokizumab 64 mg + Placebo (NCT04452474)
- 2021-11-05Results posted on the registry: CSL Behring, Placebo matching BMS-945429 + BMS-945429 (NCT01490450)
- 2021-08-26Phase 3 first posted: Novo Nordisk A/S, Ziltivekimab B + Ziltivekimab C (NCT05021835)
- 2021-07-21Results posted on the registry: R-Pharm International, LLC, Olokizumab + Placebo (NCT02760433)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision